These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29203817)

  • 1. High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.
    Alshareef A; Gupta N; Zhang HF; Wu C; Haque M; Lai R
    Sci Rep; 2017 Dec; 7(1):16863. PubMed ID: 29203817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
    BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
    Alshareef A; Zhang HF; Huang YH; Wu C; Zhang JD; Wang P; El-Sehemy A; Fares M; Lai R
    Sci Rep; 2016 Sep; 6():33710. PubMed ID: 27641368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.
    Wu C; Zhang HF; Gupta N; Alshareef A; Wang Q; Huang YH; Lewis JT; Douglas DN; Kneteman NM; Lai R
    J Hematol Oncol; 2016 Nov; 9(1):120. PubMed ID: 27821172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
    Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
    Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
    Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
    Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
    Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
    Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.
    Chen W; Guo X; Zhang C; Ke D; Zhang G; Yu Y
    Eur J Med Chem; 2019 Dec; 183():111734. PubMed ID: 31569004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK and IGF-1R as independent targets in crizotinib resistant lung cancer.
    Wilson C; Nimick M; Nehoff H; Ashton JC
    Sci Rep; 2017 Oct; 7(1):13955. PubMed ID: 29066738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells.
    Ye X; Wu F; Wu C; Wang P; Jung K; Gopal K; Ma Y; Li L; Lai R
    Cell Signal; 2014 Mar; 26(3):492-501. PubMed ID: 24291232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.
    Shang C; Hassan B; Haque M; Song Y; Li J; Liu D; Lipke E; Chen W; Giuriato S; Lai R
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
    Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
    Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 19. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
    Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.